Biochemical analysis of pbmc

Abstract

A method is provided comprising, obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample by analyzing the sample by infrared spectroscopy; and based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition. Other embodiments are also provided.

1 . A method comprising:
 obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample by analyzing the sample by infrared spectroscopy; and   based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition.   
     
     
         2 . The method according to  claim 1 , wherein generating the output comprises generating the output indicative of the presence of the solid tumor. 
     
     
         3 . The method according to  claim 1 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared (FTIR) spectroscopy, and wherein obtaining the infrared (IR) spectrum comprises obtaining a Fourier Transformed Infrared (FTIR) spectrum. 
     
     
         4 . The method according to  claim 3 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared microspectroscopy (FTIR-MSP). 
     
     
         5 . The method according to  claim 1 , wherein analyzing comprises assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 765±4 cm-1, 798±4 cm-1, 809±4 cm-1, 814±4 cm-1, 875±4 cm-1, 997±4 cm-1, 1001±4 cm-1, 1015±4 cm-1, 1103±4 cm-1, 1118±4 cm-1, 1162±4 cm-1, 1221±4 cm-1, 1270±4 cm-1, 1283±4 cm-1, 1295±4 cm-1, 1315±4 cm-1, 1341±4 cm-1, 1367±4 cm-1, 1392±4 cm-1, 1429±4 cm-1, 1440±4 cm-1, 1445±4 cm-1 and 1455±4 cm-1. 
     
     
         6 . The method according to  claim 5 , wherein analyzing comprises assessing the characteristic at at least two wavenumbers selected from the group. 
     
     
         7 . The method according to  claim 5 , wherein analyzing comprises assessing the characteristic at at least three wavenumbers selected from the group. 
     
     
         8 . The method according to  claim 5 , wherein assessing the characteristic comprises analyzing a band of the IR spectrum surrounding at least one wavenumber selected from the group. 
     
     
         9 . The method according to  claim 1 , wherein analyzing the sample comprises obtaining a second derivative of the infrared (IR) spectrum of the sample. 
     
     
         10 . The method according to  claim 1 , wherein the infrared (IR) spectrum includes an absorption spectrum, and wherein obtaining the infrared (IR) spectrum comprises obtaining the absorption spectrum. 
     
     
         11 . The method according to  claim 1 , wherein the infrared (IR) spectrum includes a reflection spectrum, and wherein obtaining the infrared (IR) spectrum comprises obtaining the reflection spectrum. 
     
     
         12 . The method according to  claim 1 , wherein generating the output comprises indicating via the output whether the solid tumor is a first type of solid tumor or a second type of solid tumor. 
     
     
         13 . The method according to  claim 1 , wherein the solid tumor includes a solid tumor in tissue selected from the group consisting of: head and neck, esophagus, and pancreas, and wherein generating the output comprises generating an output indicative of the presence of a solid tumor in tissue selected from the group. 
     
     
         14 . The method according to  claim 1 , wherein the solid tumor includes a solid tumor in tissue selected from the group consisting of: breast, gastrointestinal tract, prostate, and lung, and wherein generating the output comprises generating an output indicative of the presence of a solid tumor in tissue selected from the group. 
     
     
         15 . The method according to  claim 14 , wherein analyzing comprises assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 752±4 cm-1, 1030±4 cm-1, 1046±4 cm-1, 1128±4 cm-1, and 1237±4 cm-1, and wherein generating comprises generating an output indicative of the presence of a tumor in the breast tissue. 
     
     
         16 . The method according to  claim 14 , wherein analyzing comprises assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 797±4 cm-1, 830±4 cm-1, 893±4 cm-1, 899±4 cm-1, 1128±4 cm-1, 1298±4 cm-1, 1354 ±4 cm-1, 1714±4 cm-1 1725±4 cm-1, 1738,±4 cm-1, and 3013±4 cm-1, and wherein generating comprises generating an output indicative of the presence of a tumor in the gastrointestinal tract tissue. 
     
     
         17 . The method according to  claim 14 , wherein analyzing comprises assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 765±4 cm-1, 780±4 cm-1, 797±4 cm-1, 851±4 cm-1, 874±4 cm-1, 881±4 cm-1, 913±4 cm-1, 923±4 cm-1, 958±4 cm-1, 968,±4 cm-1, 1044±4 cm-1, 1085±4 cm-1, 1191±4 cm-1, 1241±4 cm-1, 1344±4 cm-1, 1373±4 cm-1, 1417±4 cm-1, 1458±4 cm-1, 1469±4 cm-1, 1692±4 cm-1, 1714±4 cm-1, 1728±4 cm-1, 2852±4 cm-1, and 2984±4 cm, and wherein generating comprises generating an output indicative of the presence of a tumor in the lung tissue. 
     
     
         18 . The method according to  claim 14 , wherein analyzing comprises assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 828±4 cm-1, 932±4 cm-1, 997±4 cm-1, 1059±4 cm-1, 1299±4 cm-1, 1302±4 cm-1, 1403±4 cm-1, 1454±4 cm-1, 1714±4 cm-1, 2979,±4 cm-1, and 3013±4 cm-1, and wherein generating comprises generating an output indicative of the presence of a tumor in the prostate tissue. 
     
     
         19 . A method comprising:
 obtaining an infrared (IR) spectrum of a sample of white blood cells by analyzing the sample by infrared spectroscopy; and   based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition.   
     
     
         20 . The method according to  claim 19 , wherein generating the output comprises generating the output indicative of the presence of the solid tumor. 
     
     
         21 . The method according to  claim 19 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared (FTIR) spectroscopy, and wherein obtaining the infrared (IR) spectrum comprises obtaining a Fourier Transformed Infrared (FTIR) spectrum. 
     
     
         22 . The method according to  claim 21 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared microspectroscopy (FTIR-MSP). 
     
     
         23 . A method for monitoring the effect of an anti-cancer treatment on a subject undergoing anti-cancer treatment for a solid tumor, for use with a first Peripheral Blood Mononuclear Cells (PBMC) sample separated from blood of the subject that was obtained prior to initiation of the treatment and a second PBMC sample separated from blood of the subject that was obtained after initiation of the treatment, the method comprising:
 obtaining IR spectra of the first and second PBMC samples by analyzing the first and second PBMC samples by IR spectroscopy; and   based on the IR spectra, generating an output indicative of the effect of the treatment.   
     
     
         24 . The method according to  claim 23 , wherein analyzing the first and second PBMC samples by IR spectroscopy comprises analyzing the samples by Fourier Transformed Infrared spectroscopy, and wherein obtaining the IR spectra comprises obtaining Fourier Transformed Infrared (FTIR) spectra. 
     
     
         25 . The method according to  claim 24 , wherein analyzing the first and second PBMC samples by infrared (IR) spectroscopy comprises analyzing the first and second PBMC samples by Fourier Transformed Infrared microspectroscopy (FTIR-MSP). 
     
     
         26 . The method according to  claim 23 , further comprising obtaining an IR spectrum of a third PBMC sample separated from blood of the subject that was obtained following termination of the treatment, by analyzing the third PBMC sample by IR spectroscopy. 
     
     
         27 . The method according to  claim 3 , wherein analyzing comprises assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 765±4 cm-1, 798±4 cm-1, 809±4 cm-1, 814±4 cm-1, 875±4 cm-1, 997±4 cm-1, 1001±4 cm-1, 1015±4 cm-1, 1103±4 cm-1, 1118±4 cm-1, 1162±4 cm-1, 1221±4 cm-1, 1270±4 cm-1, 1283±4 cm-1, 1295±4 cm-1, 1315±4 cm-1, 1341±4 cm-1, 1367±4 cm-1, 1392±4 cm-1, 1429±4 cm-1, 1440±4 cm-1, 1445±4 cm-1, and 1455±4 cm-1. 
     
     
         28 . The method according to  claim 27 , wherein analyzing comprises assessing the characteristic at at least two wavenumbers selected from the group. 
     
     
         29 . The method according to  claim 27 , wherein analyzing comprises assessing the characteristic at at least three wavenumbers selected from the group. 
     
     
         30 . A method comprising:
 obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample by analyzing the sample; and   based on the infrared spectrum, generating an output indicative of the presence of a solid tumor or a pre-malignant condition.   
     
     
         31 . The method according to  claim 30 , wherein generating the output comprises generating the output indicative of the presence of the solid tumor. 
     
     
         32 . A system for diagnosing a solid tumor, comprising:
 a data processor, configured to analyze an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample of a subject; and   an output unit, configured to generate an output indicative of the presence of a solid tumor, based on the infrared (IR) spectrum.   
     
     
         33 . The system according to  claim 32 , wherein the data processor is configured to calculate a second derivative of the infrared (IR) spectrum of the PBMC sample and, based on the second derivative of the infrared (IR) spectrum, to generate an output indicative of the presence of a solid tumor. 
     
     
         34 . The system according to  claim 33 , wherein the IR spectrum includes a Fourier Transformed Infrared (FTIR) spectrum, and wherein the data processor is configured to calculate a second derivative of the FTIR spectrum. 
     
     
         35 . The system according to  claim 32 , wherein the data processor is configured to analyze the infrared (IR) spectrum by assessing a characteristic of the PBMC sample at at least one wavenumber selected from the group consisting of: 765±4 cm-1, 798±4 cm-1, 809±4 cm-1, 814±4 cm-1, 875±4 cm-1, 997±4 cm-1, 1001±4 cm-1, 1015±4 cm-1, 1103±4 cm-1, 1118±4 cm-1, 1162±4 cm-1, 1221±4 cm-1, 1270±4 cm-1, 1283±4 cm-1, 1295±4 cm-1, 1315±4 cm-1, 1341±4 cm-1, 1367±4 cm-1, 1392±4 cm-1, 1429±4 cm-1, 1440±4 cm-1, 1445±4 cm-1, and 1455±4 cm-1. 
     
     
         36 . The system according to  claim 35 , wherein the data processor is configured to analyze the infrared (IR) spectrum by assessing the characteristic at at least two wavenumbers selected from the group. 
     
     
         37 . The system according to  claim 35 , wherein the data processor is configured to analyze the infrared (IR) spectrum by assessing the characteristic at at least three wavenumbers selected from the group. 
     
     
         38 . A computer program product for administering processing of a body of data, the product comprising a computer-readable medium having program instructions embodied therein, which instructions, when read by a computer, cause the computer to:
 obtain an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) by analyzing the PBMC by infrared spectroscopy; and   based on the infrared spectrum, generate an output indicative of the presence of a solid tumor.   
     
     
         39 . A method comprising:
 obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample by analyzing the sample by infrared spectroscopy; and   based on the infrared spectrum, generating an output indicative of the presence of a solid tumor in a breast tissue of a subject.   
     
     
         40 . The method according to  claim 39 , wherein analyzing comprises assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 752±4 cm-1, 1030±4 cm-1, 1046±4 cm-1, 1128±4 cm-1, and 1237±4 cm-1. 
     
     
         41 . The method according to  claim 40 , wherein analyzing comprises assessing the characteristic at at least two wavenumbers selected from the group. 
     
     
         42 . The method according to  claim 40 , wherein analyzing comprises assessing the characteristic at at least three wavenumbers selected from the group. 
     
     
         43 . The method according to  claim 39 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared (FTIR) spectroscopy, and wherein obtaining the infrared (IR) spectrum comprises obtaining a Fourier Transformed Infrared (FTIR) spectrum. 
     
     
         44 . The method according to  claim 43 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared microspectroscopy (FTIR-MSP). 
     
     
         45 . A method comprising:
 obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample by analyzing the sample by infrared spectroscopy; and   based on the infrared spectrum, generating an output indicative of the presence of a solid tumor in tissue of a gastrointestinal tract of a subject.   
     
     
         46 . The method according to  claim 45 , wherein analyzing comprises assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 797±4 cm-1, 830±4 cm-1, 893±4 cm-1, 899±4 cm-1, 1128±4 cm-1, 1298±4 cm-1, 1354±4 cm-1, 1714±4 cm-1 1725±4 cm-1, 1738,±4 cm-1, and 3013±4 cm-1. 
     
     
         47 . The method according to  claim 46 , wherein analyzing comprises assessing the characteristic at at least two wavenumbers selected from the group. 
     
     
         48 . The method according to  claim 46 , wherein analyzing comprises assessing the characteristic at at least three wavenumbers selected from the group. 
     
     
         49 . The method according to  claim 45 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared (FTIR) spectroscopy, and wherein obtaining the infrared (IR) spectrum comprises obtaining a Fourier Transformed Infrared (FTIR) spectrum. 
     
     
         50 . The method according to  claim 49 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared microspectroscopy (FTIR-MSP). 
     
     
         51 . A method comprising:
 obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample by analyzing the sample by infrared spectroscopy; and   based on the infrared spectrum, generating an output indicative of the presence of a solid tumor in lung tissue of a subject.   
     
     
         52 . The method according to  claim 51 , wherein analyzing comprises assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 765±4 cm-1, 780±4 cm-1, 797±4 cm-1, 851±4 cm-1, 874±4 cm-1, 881±4 cm-1, 913±4 cm-1, 923±4 cm-1, 958±4 cm-1, 968,±4 cm-1, 1044±4 cm-1, 1085±4 cm-1, 1191±4 cm-1, 1241±4 cm-1, 1344±4 cm-1, 1373±4 cm-1, 1417±4 cm-1, 1458±4 cm-1, 1469±4 cm-1, 1692±4 cm-1, 1714±4 cm-1, 1728±4 cm-1, 2852±4 cm-1, and 2984±4 cm. 
     
     
         53 . The method according to  claim 52 , wherein analyzing comprises assessing the characteristic at at least two wavenumbers selected from the group. 
     
     
         54 . The method according to  claim 52 , wherein analyzing comprises assessing the characteristic at at least three wavenumbers selected from the group. 
     
     
         55 . The method according to  claim 51 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared (FTIR) spectroscopy, and wherein obtaining the infrared (IR) spectrum comprises obtaining a Fourier Transformed Infrared (FTIR) spectrum. 
     
     
         56 . The method according to  claim 55 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared microspectroscopy (FTIR-MSP). 
     
     
         57 . A method comprising:
 obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample by analyzing the sample by infrared spectroscopy; and   based on the infrared spectrum, generating an output indicative of the presence of a solid tumor in a prostate tissue of a subject.   
     
     
         58 . The method according to  claim 57 , wherein analyzing comprises assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 828±4 cm-1, 932±4 cm-1, 997±4 cm-1, 1059±4 cm-1, 1299±4 cm-1, 1302±4 cm-1, 1403±4 cm-1, 1454±4 cm-1, 1714±4 cm-1, 2979,±4 cm-1, and 3013±4 cm-1. 
     
     
         59 . The method according to  claim 58 , wherein analyzing comprises assessing the characteristic at at least two wavenumbers selected from the group. 
     
     
         60 . The method according to  claim 58 , wherein analyzing comprises assessing the characteristic at at least three wavenumbers selected from the group. 
     
     
         61 . The method according to  claim 57 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared (FTIR) spectroscopy, and wherein obtaining the infrared (IR) spectrum comprises obtaining a Fourier Transformed Infrared (FTIR) spectrum. 
     
     
         62 . The method according to  claim 61 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared microspectroscopy (FTIR-MSP). 
     
     
         63 . A method comprising:
 obtaining an infrared (IR) spectrum of a Peripheral Blood Mononuclear Cells (PBMC) sample from a cancer patient by analyzing the sample by infrared spectroscopy; and   based on the infrared spectrum, generating an output indicative of a stage of the cancer.   
     
     
         64 . The method according to  claim 63 , wherein analyzing comprises assessing a characteristic of the sample at at least one wavenumber selected from the group consisting of: 865±4 cm-1, 897±4 cm-1, 924±4 cm-1, 1030±4 cm-1, 1047±4 cm-1, 1191±4 cm-1, and 1238±4 cm-1. 
     
     
         65 . The method according to  claim 64 , wherein analyzing comprises assessing the characteristic at at least two wavenumbers selected from the group. 
     
     
         66 . The method according to  claim 64 , wherein analyzing comprises assessing the characteristic at at least three wavenumbers selected from the group. 
     
     
         67 . The method according to  claim 63 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared (FTIR) spectroscopy, and wherein obtaining the infrared (IR) spectrum comprises obtaining a Fourier Transformed Infrared (FTIR) spectrum. 
     
     
         68 . The method according to  claim 67 , wherein analyzing the sample by infrared (IR) spectroscopy comprises analyzing the sample by Fourier Transformed Infrared microspectroscopy (FTIR-MSP).